^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Bladder Cancer

    Related cancers:
    1d
    Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer (clinicaltrials.gov)
    P1/2, N=29, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    New P1/2 trial
    |
    cisplatin • Jingzhuda (entinostat)
    1d
    Integration of gut microbiome and lipid metabolism reveals the anti-cancer effects of pentadecanoic acid on bladder cancer. (PubMed, BMC Med)
    Collectively, our findings demonstrate that PEA mitigates BC by reshaping the gut microbiome and modulating lipid metabolism, providing new insights into its molecular and therapeutic potential.
    Journal
    |
    APOB (Apolipoprotein B) • APOE (Apolipoprotein E)
    1d
    A Rare Case of Primary Bladder Lymphoepithelial Carcinoma. (PubMed, Arch Esp Urol)
    The patient remained recurrence-free at 11 months of follow-up after gemcitabine bladder infusion chemotherapy, arterial drug-infusion embolization, systemic chemotherapy, and immunotherapy.
    Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • ALPP (Alkaline Phosphatase, Placental) • SALL4 (Spalt Like Transcription Factor 4) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3) • TCF4 (Transcription Factor 4)
    |
    gemcitabine
    1d
    Diagnostic Values of Serum Matrix Metalloproteinase-9 and Nuclear Matrix Protein 22 for Bladder Cancer. (PubMed, Arch Esp Urol)
    Serum MMP-9 and NMP22 levels are significantly elevated in bladder cancer and correlate with TNM stage. Combined detection may improve diagnostic accuracy and clinical utility in bladder cancer diagnosis.
    Journal
    |
    MMP9 (Matrix metallopeptidase 9)
    1d
    Asperuloside Inhibits Bladder Cancer Cell Migration and Proliferation by Downregulating ATF6 Signalling Pathway and Inflammatory Factors. (PubMed, Arch Esp Urol)
    In T24 BLCA cells, ASP inhibits ATF6, which prevents apoptosis resistance and migration and alters the expression of inflammatory genes and EMT markers. According to these findings, ASP is a promising natural substance that targets the endoplasmic reticulum (ER) stress-ATF6 axis in BLCA. It has a unique multi-target capability that allows it to simultaneously control inflammation, tumour proliferation and metastasis, providing a therapeutic advantage over conventional single-target agents.
    Journal
    |
    IL6 (Interleukin 6) • CDH1 (Cadherin 1) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CCL2 (Chemokine (C-C motif) ligand 2) • CDH2 (Cadherin 2) • ATF6 (Activating Transcription Factor 6)
    1d
    NEAT1 is a therapeutic target for reversing T-cell exhaustion in bladder cancer. (PubMed, J Immunother Cancer)
    lncRNA NEAT1 serves as a modulator of the antitumor response of CD8+T cells in the bladder tumor microenvironment and may represent a therapeutic target for reversing T-cell exhaustion.
    Journal • IO biomarker
    |
    LDHA (Lactate dehydrogenase A) • CD8 (cluster of differentiation 8) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1)
    1d
    Evaluation of Safety, Tolerability and Response of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU) (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Institut Cancerologie de l'Ouest
    New P1 trial • First-in-human
    |
    Rencarex (girentuximab)
    1d
    Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, University Health Network, Toronto | Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: Sep 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
    |
    cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301)
    1d
    Natural killer cell-related gene signature predicts immune cell infiltration and improved survival in bladder cancer. (PubMed, Cytokine)
    The NK cell-related gene signature serves as a robust prognostic biomarker and predictor of immunotherapeutic efficacy in BC. These findings provide new insights into BC biology and facilitate personalized immunotherapy strategies.
    Journal • Gene Signature • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    1d
    Virus-induced APOBEC3 transmutagenesis in bladder cancer initiation. (PubMed, Sci Adv)
    "Transmutagenesis" explains how cells proximal to infected neighbors acquire cancer-initiating mutations. This hypothesis for how urothelial cancers can develop as APOBEC3 signature rich, while remaining virus-negative, suggests that a large proportion of urothelial carcinomas may be preventable by antiviral intervention.
    Review • Journal
    |
    APOB (Apolipoprotein B)
    2d
    ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors (clinicaltrials.gov)
    P=N/A, N=384, Recruiting, AstraZeneca | Trial completion date: Nov 2025 --> Apr 2026 | Trial primary completion date: Nov 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    2d
    The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial (clinicaltrials.gov)
    P2, N=262, Not yet recruiting, Chiti Arturo
    New P2 trial • Liquid biopsy
    |
    Bladder EpiCheck® • Xpert® Bladder Cancer Monitor